ACH 04Alternative Names: ACH04
Latest Information Update: 10 Nov 2016
At a glance
- Originator Ache Laboratories
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diarrhoea
Most Recent Events
- 31 Dec 2014 Phase-II clinical trials in Diarrhoea in Brazil (unspecified route) prior to December (Ache Laboratories annual report,